Kisspeptin-54 (KP-54): What the Research Shows | 2026

Table of Contents
- Quick Answer
- What Kisspeptin-54 Actually Is
- KP-54 vs KP-10: Why the Distinction Matters
- Mechanism: The Kisspeptin to GnRH Axis
- Preclinical Evidence
- Human Clinical Evidence
- Dosing
- Reconstitution
- Routes of Administration
- Safety Profile
- Drug Interactions
- Stack Considerations
- Regulatory Status
- Read Next
- Cycle Lengths
- Lab Monitoring
- Storage & Travel
Quick Answer
Kisspeptin-54 (KP-54, also called metastin) is the full-length 54-amino-acid human kisspeptin secreted by hypothalamic and placental cells. It binds the KISS1R / GPR54 receptor on GnRH neurons and triggers a pulse of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drives gonadal testosterone or estradiol release. It is the molecule used in the Imperial College London IVF trigger and hypoactive sexual desire disorder (HSDD) trial program led by Waljit Dhillo and Ali Abbara.
Twice-weekly is the maximum sustainable dosing frequency. A 2009 trial in women with hypothalamic amenorrhea (Jayasena, PMID 19820030) found that twice-daily subcutaneous KP-54 for two weeks produced tachyphylaxis: the LH and FSH response progressively weakened with each dose. A follow-up trial in 2010 using twice-weekly dosing for eight weeks preserved the response (Jayasena, PMID 20980998). Vendor protocols that recommend daily kisspeptin injections are directly contrary to the published Imperial data and should be regarded as unsafe.
KP-54 is investigational. It is not FDA-approved, not on the FDA 503A bulks list, and cannot lawfully be compounded by U.S. pharmacies. It is not DEA-scheduled. Every clinical trial of KP-54 to date has been conducted under IRB and regulatory authorization, not as at-home dosing.
Kisspeptin-54 is the most studied non-approved peptide in reproductive endocrinology. Twenty years of clinical research from a single academic group, Imperial College London under Waljit Dhillo, has produced first-in-human dose-finding work, two Phase 2 IVF trigger trials, four head-to-head sexual brain processing studies, and a 2025 breakthrough in intranasal delivery. The evidence base for short-term controlled administration is genuinely strong. The evidence base for chronic at-home dosing is essentially absent and, in the one chronic-dosing scenario that has been published, the safety signal points to tachyphylaxis rather than sustained benefit.
This guide reads the data as it is, separates the IVF trigger story from the testosterone-boost framing that circulates on vendor pages, and surfaces the dosing-frequency safety rule that is too often buried in vendor protocols.
What Kisspeptin-54 Actually Is
The KISS1 gene was first identified in 1996 as a melanoma metastasis suppressor (the “kiss” prefix is a tribute to Hershey, Pennsylvania, the home of Hershey’s Kisses, where the discovery laboratory was located). Two simultaneous 2001 papers (Ohtaki et al., Nature, PMID 11385580; Kotani et al., Journal of Biological Chemistry, PMID 11457843) showed that the KISS1 gene product was the natural ligand for an orphan G-protein-coupled receptor then called GPR54, now KISS1R. The reproductive role was nailed down two years later: parallel loss-of-function genetics from Seminara et al. in New England Journal of Medicine (PMID 14573733) and de Roux et al. in PNAS (PMID 12944565) showed that homozygous inactivating mutations in GPR54 cause hypogonadotropic hypogonadism, meaning patients fail to enter puberty. The complementary observation, that loss-of-function mutations in the KISS1 gene itself produce the same phenotype, was reported by Topaloglu in NEJM in 2012 (PMID 22335740).
Together, these papers established that kisspeptin signaling through KISS1R is necessary for puberty and adult reproductive function in humans. Kisspeptin sits one step upstream of GnRH in the hypothalamic-pituitary-gonadal (HPG) axis. Without it, the axis does not fire.
The KISS1 gene is initially translated as a 145-amino-acid prepropeptide, which is post-translationally cleaved into shorter active fragments. The longest stable secreted form is the 54-amino-acid kisspeptin-54 (KP-54), with molecular weight approximately 6,070 daltons. Shorter forms include KP-14, KP-13, and the decapeptide KP-10 (molecular weight approximately 1,302 daltons). All four share the same C-terminal 10-amino-acid sequence, YNWNSFGLRF-NH2, which is the receptor-binding pharmacophore. The C-terminal amide is essential for KISS1R binding; vendors selling non-amidated material are selling an inactive product.
KP-54 is sold by research-peptide vendors as a lyophilized acetate salt, typically as 1 mg or 5 mg vials at greater than 95% purity, CAS 374675-21-5. The molecular weight discrepancy between KP-54 and KP-10 is one of the most common vendor labeling errors: any product page listing “kisspeptin-54” alongside a molecular weight in the 1,300 range is selling KP-10, not KP-54.
KP-54 vs KP-10: Why the Distinction Matters
The two kisspeptins are not interchangeable. They share the same receptor-binding decapeptide, but their pharmacokinetics and central nervous system penetration differ in ways that matter clinically.
d’Anglemont de Tassigny et al. published the definitive head-to-head comparison in PLOS ONE in 2017 (PMID 28464043). In adult male mice:
- Plasma half-life: KP-54 approximately 32 minutes vs. KP-10 approximately 4 minutes, an eight-fold difference.
- LH response duration: A single peripheral KP-54 injection produced LH that remained elevated at two hours. Peripheral KP-10 produced a sharper but much shorter LH spike.
- Brain penetration: Only KP-54 induced c-FOS expression in GnRH neurons behind the blood-brain barrier after peripheral injection. Even when KP-10 was redosed every 10 minutes for one hour to compensate for its short half-life, it did not reproduce the c-FOS activation seen with a single KP-54 dose.
The authors interpret this as KP-54 having access to GnRH neuron cell bodies through the partial-BBB region at the median eminence, while peripheral KP-10 acts predominantly on terminals outside the BBB and is cleared before reaching the cell bodies. This finding is the mechanistic reason every Imperial College London clinical trial in IVF triggering, hypothalamic amenorrhea, and HSDD uses KP-54, not KP-10. KP-10 still has utility in mechanistic dose-response physiology research, but it is not the clinical-translation molecule.
Practical implication: cross-shopping a 1 mg KP-10 vial against a 5 mg KP-54 vial on price-per-milligram makes no clinical sense, because the molecules behave differently after injection and target different research questions.
Mechanism: The Kisspeptin to GnRH Axis
KP-54 is produced by two populations of hypothalamic kisspeptin neurons. The first is the arcuate (ARC) nucleus, where kisspeptin neurons co-express neurokinin B and dynorphin (the “KNDy” neurons) and drive pulsatile GnRH release. The second is the rostral periventricular area of the third ventricle, which drives the preovulatory LH surge in females. KP-54 binds KISS1R on GnRH neuron cell bodies and terminals, increasing neuron firing rate and triggering GnRH release into the hypophyseal portal circulation. GnRH then stimulates pituitary gonadotropes to release LH and FSH, and the gonadotropins drive testicular testosterone production in men and ovarian follicle development plus estradiol in women.
KP-54 also acts outside the HPG axis. Comninos et al. (PMID 28112678, 2017 in Journal of Clinical Investigation) demonstrated using functional MRI that intravenous KP-54 modulates BOLD responses in the limbic system, anterior cingulate, and insula during viewing of sexual and bonding-related stimuli in healthy men. A follow-up resting-state fMRI study (Comninos 2018, JCI Insight, PMID 30333302) showed kisspeptin modulates default-mode and limbic-system connectivity. Owens et al. (Human Reproduction 2018, PMID 29206944) showed kisspeptin acts directly on human granulosa lutein cells in vitro, suggesting dual peripheral and central action during the IVF trigger.
KP-54 also rises 7,000-fold across normal pregnancy, largely from placental sources. The physiologic role of pregnancy kisspeptin is incompletely understood but is consistent with a non-toxic safety profile at high circulating levels.
Preclinical Evidence
The receptor pharmacology is well established. KP-54 administered centrally (intracerebroventricular) or peripherally robustly stimulates LH and FSH in rats, mice, sheep, and non-human primates. KP-54 and KP-10 both trigger an LH surge in seasonally anestrous ewes and prepubertal monkeys, consistent with the role of kisspeptin in puberty onset.
The original anti-metastasis finding has been characterized in xenograft models. KISS1R activation reduces cancer-cell motility and chemotaxis in melanoma, breast, and other tumor cell lines. No clinical anti-cancer program has reached Phase 2 or Phase 3.
Human Clinical Evidence
This is where KP-54 has the strongest data of any non-approved peptide. The Imperial College London group has run essentially every controlled clinical trial.
A note on the “2018 NEJM Abbara” citation: A 2018 New England Journal of Medicine paper by Abbara on kisspeptin-54 IVF triggering circulates on biohacker forums but does not exist. PubMed restricted to NEJM shows only five kisspeptin-related papers in that journal, all of which are loss-of-function genetics studies or commentaries, not KP-54 trials. The closest intended citations are Jayasena 2014 in Journal of Clinical Investigation (PMID 25036713) or Abbara 2017 in Human Reproduction (PMID 28854728). Verify any source that cites a 2018 NEJM Abbara paper.
Foundational Human Pharmacology
Dhillo et al., 2005, Journal of Clinical Endocrinology and Metabolism (PMID 16174713). First-in-human study. A 90-minute intravenous infusion of KP-54 at 4 pmol/kg/min in four healthy men robustly stimulated LH, FSH, and testosterone within 90 minutes. No adverse events. This established that KP-54 is biologically active in humans and that the IV route works.
Jayasena et al., 2009, Journal of Clinical Endocrinology and Metabolism (PMID 19820030). The critical safety paper. Subcutaneous KP-54 at 6.4 nmol/kg in five women with hypothalamic amenorrhea acutely stimulated LH and FSH. However, twice-daily SC dosing for two weeks produced progressive desensitization: by the end of the two weeks, the gonadotropin response was substantially reduced compared with the first injection. This is the tachyphylaxis finding that anchors every dosing-frequency recommendation downstream.
Jayasena et al., 2010, Clinical Pharmacology and Therapeutics (PMID 20980998). The follow-up. Twice-weekly SC KP-54 dosing in HA women for eight weeks preserved the gonadotropin response and stimulated reproductive hormones over the full eight-week period. This established that dosing frequency is the key variable: once or twice weekly works, twice daily does not.
Jayasena et al., 2013, Journal of Clinical Endocrinology and Metabolism (PMID 24030945). Counterpoint study. Twice-daily SC KP-54 in healthy (non-HA) cycling women for one cycle did not disrupt menstruation. The tachyphylaxis observation appears specific to chronic frequent dosing in HA, where endogenous HPG drive is already deficient. In healthy women on intact HPG drive, the system reasserts itself. This does not change the dosing-frequency recommendation for off-label use, because most off-label users do not have intact HA-grade baseline data to know which scenario they are in.
Jayasena et al., 2014, Journal of Clinical Endocrinology and Metabolism (PMID 24517142). IV KP-54 infusion in HA women restored normal LH pulse frequency, demonstrating that kisspeptin can rescue physiological gonadotropin pulsatility. This is the mechanistic basis for HA being a target indication.
IVF Trigger: The Strongest Clinical Signal
The Imperial group’s IVF trigger program established KP-54 as a candidate replacement for human chorionic gonadotropin (hCG) and GnRH-agonist triggers of final oocyte maturation, specifically to reduce ovarian hyperstimulation syndrome (OHSS) risk.
Jayasena et al., 2014, Journal of Clinical Investigation (PMID 25036713). The seminal IVF paper. 53 women with anovulatory infertility undergoing IVF received a single subcutaneous KP-54 injection (1.6, 3.2, 6.4, or 12.8 nmol/kg) approximately 36 hours before oocyte retrieval to trigger final oocyte maturation. Mature oocytes were retrieved in 92% of subjects. Live births occurred. This is the proof-of-concept paper, published in JCI, not NEJM.
Abbara et al., 2015, Journal of Clinical Endocrinology and Metabolism (PMID 26192876). Open-label trial in 60 women at high risk of OHSS. SC KP-54 at 9.6 nmol/kg produced 95% oocyte maturation with no cases of moderate-to-severe OHSS. Established the safety advantage of KP-54 trigger over hCG in the high-OHSS-risk population.
Abbara et al., 2017, Human Reproduction (PMID 28854728). Phase 2 randomized controlled trial in 62 women at high OHSS risk: single SC KP-54 dose vs. a second dose of KP-54 ten hours after the first. The second-dose arm produced significantly higher oocyte maturation rates without increasing OHSS risk. This is the methodologically strongest KP-54 IVF trial published to date (RCT design, OHSS-risk-enriched population, dose-optimization endpoint, Phase 2 status).
Abbara et al., 2018, Clinical Endocrinology (PMID 29446481). Compared OHSS rates following KP-54 vs. hCG vs. GnRH-agonist triggers across the Imperial trial cohort. KP-54 had OHSS rates comparable to or lower than GnRH-agonist, and both lower than hCG. Supports KP-54 as the safest IVF trigger currently studied in high-risk patients.
Owens et al., 2018, Human Reproduction (PMID 29206944). Mechanistic substudy showing KP-54 acts directly on granulosa lutein cells in vitro in addition to its indirect pituitary-mediated effect during IVF trigger.
Abbara et al., 2020, Journal of Clinical Investigation (PMID 33196464). Expanded program combining KP-54 with a small-molecule KISS1R agonist in HA plus IVF settings.
Sexual and Emotional Brain Processing: The HSDD Trials
This is the second cluster of high-quality KP-54 evidence and the source of the “kisspeptin for libido” framing on vendor sites. Read the actual trials before trusting that framing.
Comninos et al., 2017, Journal of Clinical Investigation (PMID 28112678). IV KP-54 infusion (1 nmol/kg/h for 75 minutes) in 29 healthy heterosexual men during fMRI while viewing sexual and bonding stimuli. KP-54 enhanced limbic-system BOLD responses to sexual stimuli and bonding-related stimuli, suggesting CNS effects beyond the reproductive axis.
Comninos et al., 2018, JCI Insight (PMID 30333302). Resting-state fMRI follow-up showing KP-54 modulates default-mode and limbic network connectivity in patterns consistent with enhanced sexual-emotional processing.
Thurston et al., 2022, JAMA Network Open (PMID 36287566). Randomized, double-masked, placebo-controlled crossover trial in 32 premenopausal women with hypoactive sexual desire disorder (HSDD). 75-minute IV KP-54 infusion at 1 nmol/kg/h. KP-54 enhanced sexual brain processing and attraction-related brain activity vs. placebo, with corresponding psychometric improvements. No adverse events.
Thurston et al., 2023, JAMA Network Open (PMID 36735255). Companion trial in 32 men with HSDD, same crossover design, same 75-minute IV KP-54 at 1 nmol/kg/h. KP-54 enhanced sexual brain processing and increased penile tumescence compared with placebo. This is the most clinically tangible behavioral endpoint of the entire KP-54 program.
The HSDD trials are real and the effect sizes are not trivial. They are also short-term (single 75-minute infusion) and IV-administered. There is no published chronic at-home regimen and no Phase 3 program targeting HSDD as a labeled indication. The “kisspeptin restores libido” framing on vendor pages is extrapolating from a 75-minute IV infusion to a weeks-long subcutaneous self-administration protocol that has never been studied.
The 2025 Intranasal Breakthrough
Mills et al., 2025, EBioMedicine (PMID 40215751). Intranasal KP-54 at 12.8 nmol/kg produced clinically significant LH rises in healthy men, healthy women, and HA patients, without adverse events. This is the first published demonstration of non-invasive KP-54 delivery and changes the clinical-development calculus, because the IV and SC requirement was the largest practical barrier to broader use. Note that the trial used a custom nasal-delivery device; off-label use with a generic research-grade nasal sprayer is not equivalent to the trial setup, and bioavailability will vary.
Honest Characterization
What is proven by the literature:
- KP-54 acutely raises LH, FSH, and downstream gonadal steroids in healthy men, healthy women, women with HA, and women undergoing IVF.
- KP-54 triggers oocyte maturation with low OHSS risk in high-OHSS-risk IVF patients (Phase 2 RCT level evidence).
- KP-54 modulates sexual and emotional brain processing in healthy and HSDD adults under short-term IV infusion conditions.
- Intranasal KP-54 delivery works as of 2025 under a custom-device protocol.
What is not proven:
- Chronic, weeks-to-months self-administered KP-54 dosing improves any patient-reported outcome (no such trial exists).
- KP-54 raises testosterone for sustained physiologic benefit at clinically relevant magnitude (HRT-equivalent claims are vendor extrapolation).
- Oral, transdermal, or sublingual KP-54 routes work (only IV, SC, and IN are published).
- KP-54 has efficacy outside the Imperial College London group’s hands (no independent confirmatory program of the IVF trigger or HSDD findings exists).
What is contraindicated by the data:
- Twice-daily chronic SC KP-54 in HA women caused tachyphylaxis (Jayasena 2009, PMID 19820030). Vendor protocols recommending daily or twice-daily kisspeptin injections are directly contrary to the published Imperial regimen.
Dosing
The published trial doses are documented below. Note that these are clinical-trial regimens administered under IRB and physician supervision, not self-administration recommendations.
| Setting | Dose | Route | Frequency | Source |
|---|---|---|---|---|
| First-in-human, healthy men | 4 pmol/kg/min over 90 min | IV infusion | Single | Dhillo 2005, PMID 16174713 |
| HA women, acute | 6.4 nmol/kg | SC | Single | Jayasena 2009, PMID 19820030 |
| HA women, chronic | 6.4 nmol/kg | SC | Twice-weekly for 8 weeks | Jayasena 2010, PMID 20980998 |
| IVF trigger, first dose | 1.6 to 12.8 nmol/kg | SC | Single, 36 h pre-retrieval | Jayasena 2014, PMID 25036713 |
| IVF trigger, OHSS-risk | 9.6 nmol/kg | SC | Single | Abbara 2015, PMID 26192876 |
| IVF trigger, second dose | 9.6 nmol/kg | SC | Second dose at +10 h | Abbara 2017, PMID 28854728 |
| HSDD, brain imaging | 1 nmol/kg/h for 75 min | IV | Single infusion | Thurston 2022/2023, PMID 36287566 and 36735255 |
| Healthy and HA, intranasal | 12.8 nmol/kg | Intranasal | Single | Mills 2025, PMID 40215751 |
Converting nmol/kg to milligrams
KP-54 molecular weight is approximately 6,070 g/mol, so 1 nmol equals 6.07 micrograms. For a 70 kg adult:
- 6.4 nmol/kg × 70 kg = 448 nmol × 6.07 μg/nmol = approximately 2.7 mg per SC dose (HA range)
- 9.6 nmol/kg × 70 kg = 672 nmol × 6.07 = approximately 4.1 mg per SC dose (OHSS-risk IVF trigger)
- 12.8 nmol/kg × 70 kg = 896 nmol × 6.07 = approximately 5.4 mg per dose (highest IVF arm, also intranasal)
- 1 nmol/kg/h × 70 kg × 75 min = approximately 87.5 nmol = approximately 0.53 mg per 75-minute IV infusion (HSDD trials)
A single clinical dose of KP-54 is in the milligram range, orders of magnitude higher than the microgram doses used for KP-10. This matters for vial-size and cost economics: a 5 mg KP-54 vial is essentially one IVF-trigger dose.
Dosing Frequency: The Critical Safety Rule
Twice-weekly is the maximum sustainable frequency, based on the head-to-head comparison between Jayasena 2009 (twice-daily, produced tachyphylaxis after two weeks, PMID 19820030) and Jayasena 2010 (twice-weekly for eight weeks, preserved response, PMID 20980998).
Vendor protocols circulating online sometimes recommend 1 mg SC daily or every other day. This pattern matches the high-frequency dosing in the Jayasena 2009 HA cohort that produced tachyphylaxis. There is no published clinical trial supporting daily kisspeptin dosing. Do not use a daily regimen. If a vendor protocol recommends daily injections, that protocol is contrary to published data.
Reconstitution
Research KP-54 is sold as a lyophilized powder, typically 1 mg or 5 mg per vial, as the acetate salt at greater than 95% purity.
Reconstitute in bacteriostatic water (BAC water) or 0.9% sodium chloride. For an IV-infusion application, some Imperial protocols use sterile water with 0.1% bovine serum albumin to prevent peptide adsorption to glass at the dilute concentrations required; this is rarely available in research-peptide kits and is not necessary for SC bolus administration.
Suggested working concentrations for a 5 mg vial reconstituted with 2 mL of BAC water yield 2.5 mg/mL, which conveniently delivers a 2.5 mg SC dose in 1.0 mL or a 4 mg dose in 1.6 mL using an insulin syringe with extended markings.
Storage: lyophilized vials at minus 20 degrees C, desiccated, are stable for at least two years. Reconstituted KP-54 should be stored at 2 to 8 degrees C and used within two weeks; or aliquot and freeze at minus 20 degrees C for up to three months. Avoid repeated freeze-thaw cycles.
Routes of Administration
- Subcutaneous bolus. Used in all IVF trigger trials (Jayasena 2014 JCI; Abbara 2015; Abbara 2017) and the HA tachyphylaxis study (Jayasena 2009). The route most consistent with off-label self-administration in a research-peptide setting.
- Intravenous infusion or bolus. Used in initial pharmacokinetic work (Dhillo 2005), HA infusion physiology (Jayasena 2014 JCEM), and all brain-imaging trials (Comninos 2017, Thurston 2022 and 2023). Requires sterile preparation and slow infusion; not realistic for self-administration outside a clinic.
- Intranasal. Mills 2025 (PMID 40215751). Requires a calibrated nasal-delivery device; informal use of a generic nasal sprayer does not reproduce the trial bioavailability.
- Oral, sublingual, transdermal. No published pharmacokinetic or efficacy data in humans. The peptide is large (54 amino acids, approximately 6,070 daltons) and would be degraded by intestinal proteases. Vendor claims of oral or sublingual kisspeptin bioavailability are not supported by published data.
Safety Profile
Across the entire Imperial College London KP-54 program, more than 250 subjects have been exposed across all cited trials, with no serious drug-related adverse events reported. This is consistent across men, women, healthy volunteers, HA patients, IVF patients, and HSDD patients, and across IV, SC, and IN routes.
Most common adverse events:
- Mild injection-site reactions with SC dosing (occasional bruising or soreness, no anaphylaxis).
- Transient nausea or headache at higher SC doses (rare).
- No effect on cardiovascular endpoints (blood pressure, heart rate, QT interval all unchanged in trial settings).
- No effect on blood glucose, hepatic markers, or renal markers in short-term dosing.
The single most important safety-relevant finding is tachyphylaxis with frequent dosing (Jayasena 2009, PMID 19820030). Twice-daily SC dosing for two weeks in HA women progressively reduced the LH and FSH response. This is mechanistically expected for a G-protein-coupled receptor agonist (the receptor downregulates) and is the basis for the twice-weekly maximum frequency rule. Vendor protocols that recommend daily dosing are setting users up for diminishing returns at best and a desensitized HPG axis at worst.
Other safety-relevant observations:
- OHSS-protective effect when used as IVF trigger (Abbara 2015, PMID 26192876; Abbara 2018, PMID 29446481). KP-54 does not cause OHSS at the rates seen with hCG triggers in the high-risk population.
- No tumor-promotion signal in published trials despite the original KISS1 metastasis-suppressor biology. Trial cohorts are small and short, so absence of signal is not absence of risk; long-term oncology safety has not been established.
- No published pregnancy-exposure data for chronic dosing. KP-54 is administered around the time of ovulation in IVF trials, but after-conception exposure has not been formally studied. Placental kisspeptin rises massively during normal pregnancy, which provides some natural-history reassurance, but no formal safety data exists for chronic exogenous dosing during pregnancy.
- No data in adolescents, prepubertal children, or postmenopausal women beyond exploratory dosing in physiology research.
Practical Contraindications
These are extrapolated from the mechanism, because no FDA label exists.
- Active hormone-dependent malignancy (breast, prostate, endometrial). KP-54 raises gonadal steroids, which could theoretically aggravate hormone-sensitive tumor growth.
- Pregnancy (formal safety data absent; place caution).
- Known hypersensitivity to kisspeptin or excipients.
Drug Interactions
No formally studied human drug-drug interactions exist. Mechanism-based theoretical considerations:
GnRH agonists or antagonists (leuprolide, cetrorelix, ganirelix, degarelix): both classes act on the same downstream axis. KP-54 stimulates GnRH release; GnRH antagonists block the pituitary response to that release. In IVF protocols, GnRH antagonists are sometimes deliberately combined with KP-54 (antagonist for cycle control, KP-54 for trigger). Co-administration is a clinical-trial design choice, not a contraindication, but it should not be attempted as self-administration.
Exogenous testosterone, TRT, hCG, or clomiphene: KP-54 acts upstream of the pituitary-gonadal axis. Exogenous testosterone suppresses GnRH, LH, and FSH via negative feedback at the hypothalamus and pituitary. Co-administration is physiologically antagonistic; KP-54 tries to stimulate an axis that exogenous testosterone is actively suppressing. There is no published data on KP-54 in TRT users.
GLP-1 receptor agonists (semaglutide, tirzepatide): no direct receptor-level interaction. Some indirect effect via the suppression of LH and testosterone reported in GLP-1 trials is possible, but no controlled co-administration study exists.
Estrogen or progestin contraceptives: suppress endogenous GnRH, LH, and FSH via negative feedback. Would theoretically attenuate the LH and FSH response to KP-54. Not formally studied.
CYP-metabolized drugs: KP-54 is a peptide cleared by proteolysis, not CYP metabolism. No CYP-mediated drug interactions are expected.
5-alpha-reductase inhibitors (finasteride, dutasteride): block conversion of testosterone to DHT but do not affect testosterone production. Theoretically compatible with KP-54.
Stack Considerations
KP-54 is not a conventional biohacker stack ingredient. Stacks worth considering, all without controlled co-administration data:
KP-10: the shorter sibling. Researchers sometimes use both for mechanism comparison. Not a recreational stack. The Imperial group’s mechanism paper (d’Anglemont de Tassigny 2017, PMID 28464043) explicitly concludes KP-54 is the more clinically translatable molecule. Vendor copy that suggests stacking KP-10 plus KP-54 has no clinical basis.
GH-axis peptides (sermorelin, ipamorelin, CJC-1295, tesamorelin): different axis (GH and IGF-1, not HPG). No mechanistic conflict, but also no synergy data.
Aromatase inhibitors (anastrozole, exemestane): sometimes proposed to control estradiol rise after KP-54 raises testosterone. No clinical data. Plausible mechanistically; contraindicated by lack of safety information outside medical supervision.
Stacks contraindicated by the data:
- Chronic frequent KP-54 dosing at daily or twice-daily intervals for weeks (tachyphylaxis, Jayasena 2009).
- KP-54 plus exogenous testosterone or anabolic steroids: direct physiological antagonism.
For practical syringe-combination questions: KP-54 doses are in the milligram range and require larger reconstituted volumes (typically 0.2 to 0.5 mL per shot) than the microgram-dosed GH-axis peptides commonly mixed in a single syringe (BPC-157, TB-500, CJC, ipamorelin). Do not mix KP-54 with other peptides in one syringe; no compatibility data exists, and the dose-volume mismatch makes accurate co-dosing difficult anyway.
Regulatory Status
- FDA approval: None. Kisspeptin-54 does not appear in Drugs@FDA. No approved KP-54 product exists anywhere in the world.
- FDA 503A bulks list: Not listed. Kisspeptin-54 is not in 21 CFR 216.23 and is not a component of any FDA-approved drug. It cannot lawfully be compounded by a 503A pharmacy in the United States.
- DEA scheduling: Not scheduled. Not a controlled substance.
- FDA designations: No orphan drug, no Fast Track, no Breakthrough Therapy as of June 2026.
- International: Not approved in the EU, UK, Australia, Canada, or Japan. Investigational only. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued Clinical Trial Authorisations for the Imperial College London KP-54 program; this is investigational use, not commercial approval.
- Commercial sponsor: None currently advancing KP-54 toward an NDA. Much of the pharmaceutical-industry attention in this space has shifted to small-molecule KISS1R agonists, which would be orally bioavailable and longer-acting.
Bottom line: KP-54 has the strongest human evidence base of any non-approved peptide in the Toolkit catalog, but it has not been pursued by a commercial sponsor and remains investigational in the strict regulatory sense.
Read Next
- Kisspeptin-10 (KP-10): the shorter decapeptide sibling. Different pharmacokinetics, different research applications. Read the KP-10 guide before assuming KP-54 and KP-10 are interchangeable.
- PT-141 (Bremelanotide): FDA-approved (Vyleesi) melanocortin-4 receptor agonist for premenopausal women with HSDD. The approved alternative for sexual-desire applications.
- Oxytocin: the other neuropeptide commonly linked to bonding and sexual function research.
- Triptorelin and other GnRH analogs: the next-step-down-the-axis modulators of the HPG system. Useful framing for understanding what KP-54 is upstream of.
Sources and verification: All clinical claims in this article cite a PubMed-indexed reference by PMID. The source dossier (RESEARCH-kisspeptin-54.md) lists 28 PMIDs verified against NCBI E-utilities on 2026-06-21. The “2018 NEJM Abbara” citation that occasionally circulates does not exist; the closest intended references are Jayasena 2014 in Journal of Clinical Investigation (PMID 25036713) and Abbara 2017 in Human Reproduction (PMID 28854728).
This guide is editorial. It is not medical advice and not a treatment recommendation. Kisspeptin-54 is an investigational research peptide and is not approved by the FDA or any equivalent regulatory body. Any use should be discussed with a qualified clinician.
Cycle Lengths
Cycling summary: No established cycling protocol for this peptide in the published literature. Community protocols vary; consult a compounding-focused clinician for a personalized plan.
Cycle timing should be informed by the peptide’s half-life, receptor tachyphylaxis profile (if applicable), and personal response monitored through lab work. Log both on-cycle and off-cycle biomarkers to understand recovery kinetics.
Lab Monitoring
Kisspeptin 54 is a research-tier healing peptide with no established peripheral efficacy biomarker. Lab monitoring should be prudent general-health surveillance rather than efficacy tracking. The panels below cover organ systems most relevant during peptide research use.
Baseline (before starting): CBC with differential, comprehensive metabolic panel (CMP) covering LFTs and renal function, fasting lipid panel, hs-CRP for inflammatory baseline, fasting glucose, and HbA1c if metabolic risk factors are present. Age-appropriate cancer screening is prudent given rodent-only data on healing/angiogenic activity for most research peptides in this class.
During use: repeat CMP + CBC every 8-12 weeks. Repeat hs-CRP alongside if using for inflammatory conditions to track the inflammatory read against symptom response. Watch trends in ALT/AST (liver) and eGFR (renal) rather than single readings.
What to flag to a physician: injection-site erythema or nodule formation, unexplained weight changes, new joint or mass symptoms, any lab value trending outside reference range across two consecutive draws.
For the full class-wide monitoring framework and a plain-language comparison of DTC lab services for peptide users, see the Peptide Lab Testing pillar guide.
Storage & Travel
Storage
Lyophilized powder: Lyophilized powder freezer -20°C (-4°F) for long-term storage; stable at room temperature for shipping and short-term handling.
Reconstituted: Refrigerate reconstituted vial at 2-8°C (36-46°F); use within ~28 days per USP <797> peptide stability guidance. Never freeze a reconstituted vial, since freeze-thaw cycles damage peptide bonds and reduce potency.
Travel
Domestic flights: pack reconstituted vials in an insulated cooler with reusable ice packs. The TSA 3-1-1 rule limits liquids to 100 mL per container in carry-on; a 3-5 mL peptide vial passes with room to spare. Keep pharmacy or vendor documentation visible for TSA questions. Lyophilized powder in original sealed vial does not require cooling for short trips.
International travel: Kisspeptin 54 is a research peptide in most jurisdictions with varying import restrictions — check the destination country’s rules before travel. Carry a physician’s letter if the peptide was prescribed by a compounding-focused clinician.
Road trips: keep the cooler in the cabin, not the trunk, during summer. Hotel mini-fridges vary in temperature stability; an insulated bag inside the mini-fridge adds a buffer.
Emergency out-of-fridge: reconstituted Kisspeptin 54 at room temperature under 24 hours is generally still viable per USP stability guidance. Longer excursions or temperatures above 30°C compromise potency; discard and reconstitute a fresh vial.






